The David H. Koch Institute for Integrative Cancer Research at MITThe David H. Koch Institute for Integrative Cancer Research at MIT

Massachusetts Institute of Technology

National Cancer Institute Cancer Center

Science + Engineering... Conquering Cancer Together

Immune Engineering Symposium 2017

October 16-17, 2017

Kresge Auditorium, MIT

Biological, chemical, and materials engineers are engaged at the forefront of immunology research. At their disposal is an analytical toolkit honed to solve problems in the petrochemical and materials industries, which share the presence of complex reaction networks, and convective and diffusive molecular transport. Powerful synthetic capabilities have also been crafted: binding proteins can be engineered with effectively arbitrary specificity and affinity, and multifunctional nanoparticles and gels have been designed to interact in highly specific fashions with cells and tissues. Fearless pursuit of knowledge and solutions across disciplinary boundaries characterizes this nascent discipline of immune engineering, synergizing with immunologists and clinicians to put immunotherapy into practice.

Register now



7:00 - 8:15  Registration

8:15 - 8:30  Introductory Remarks
Darrell Irvine | MIT, Koch Institute; HHMI
K. Dane Wittrup | MIT, Koch Institute

8:30 - 9:45  Session I
Moderator: Douglas Lauffenburger | MIT, Biological Engineering and Koch Institute

Garry P. Nolan - Stanford University School of Medicine
Pathology from the Molecular Scale on Up

Susan Napier Thomas - Georgia Institute of Technology
Transport Barriers in the Tumor Microenvironment: Drug Carrier Design for Therapeutic Delivery to Sentinel Lymph Nodes

Douglas Lauffenburger - MIT, Biological Engineering and Koch Institute
Integrative Multi-Omic Analysis of Tissue Microenvironment in Inflammatory Pathophysiology

9:45 - 10:15  Break

10:15 - 11:30  Session II
Moderator: Tyler Jacks | MIT, Koch Institute; HHMI

Tyler Jacks - MIT, Koch Institute; HHMI
Using Genetically Engineered Mouse Models to Probe Cancer-Immune Interactions

Wendell Lim - University of California, San Francisco
Synthetic Immunology: Hacking Immune Cells

Darrell Irvine - MIT, Koch Institute; HHMI
Engineering Enhanced Cancer Vaccines to Drive Combination Immunotherapies

11:30 - 1:00  Lunch Break

1:00 - 2:15  Session III
Moderator: Darrell Irvine | MIT, Koch Institute; HHMI

Nicholas P. Restifo - National Cancer Institute
Extracellular Potassium Regulates Epigenetics and Efficacy of Anti-Tumor T Cells

Jennifer Elisseeff - Johns Hopkins University
The Adaptive Immune Response to Biomaterials and Tissue Repair

Marcela Maus - Massachusetts General Hospital
Engineering Better T Cells

2:15 - 2:45  Break

2:45 - 4:00  Session IV
Moderator: Arup K. Chakraborty | MIT, IMES

Laura Walker - Adimab, LLC
Molecular Dissection of the Human Antibody Response to Respiratory Syncytial Virus

Arup K. Chakraborty - MIT, Institute for Medical Engineering & Science
How to Hit HIV Where it Hurts

William Schief - The Scripps Research Institute
HIV Vaccine Design Targeting the Human Naive B Cell Repertoire



8:30 - 9:45  Session V
Moderator: Stefani Spranger | MIT, Koch Institute

K. Christopher Garcia - Stanford University
Exploiting T Cell and Cytokine Receptor Structure and Mechanism to Develop New Immunotherapeutic Strategies

Stefani Spranger - MIT, Koch Institute
Batf3-DC as Mediators of the T Cell-Inflamed Tumor Microenvironment

George Georgiou - University of Texas at Austin
The Human Circulating Antibody Repertoire in Infection, Vaccination or Cancer

9:45 - 10:15  Break

10:15 - 11:30  Session VI
Moderator: K. Dane Wittrup | MIT, Koch Institute

Harvey Lodish - Whitehead Institute and Koch Institute
Engineered Erythrocytes Covalently Linked to Antigenic Peptides Can Protect Against Autoimmune Disease

Sai Reddy - ETH Zurich
Molecular Convergence Patterns in Antibody Responses Predict Antigen Exposure

K. Dane Wittrup - MIT, Koch Institute
Temporal Programming of Synergistic Innate and Adaptive Immunotherapy

11:30 - 1:00  Lunch Break

1:00 - 2:15  Session VII
Moderator: Michael Birnbaum | MIT, Koch Institute

Kai Wucherpfennig - Dana-Farber Cancer Institute
Discovery of Novel Targets for Cancer Immunotherapy

Michael Birnbaum - MIT, Koch Institute
An Unbiased Determination of pMHC Repertoires for Better Antigen Prediction

Jennifer R. Cochran - Stanford University
Innate and Adaptive Integrin-targeted Combination Immunotherapy

2:15 - 2:45  Break

2:45 - 3:35  Session VIII
Moderator: Jianzhu Chen | MIT, Koch Institute

Jennifer Wargo - MD Anderson Cancer Center
Understanding Responses to Cancer Therapy: The Tissue is the Issue, but the Scoop is in the Poop

Jianzhu Chen - MIT, Koch Institute
Modulating Macrophages in Cancer Immunotherapy


Register now

Related Items

Register now




Adimab, LLC
Dragonfly Therapeutics, Inc.


Compass Therapeutics, LLC
Janssen Research & Development, LLC
Selecta Biosciences, Inc.
Takeda Oncology


SQZ Biotech
Synlogic, Inc.
Third Rock Ventures
Unum Therapeutics, Inc.